Reading Time: 2 minutes
I consider the enthusiasm surrounding Hims & Hers to be premature. Eight votes in favor against six against with one abstention – with this slim majority, an FDA advisory committee recommends releasing the peptide BPC-157 for compounding in pharmacies. To me, it is this very narrow margin that is the real news: The recommendation does not bind the agency, does not replace a license, and must go through a formal rule-making process first. The fact that the FDA’s own scientists are pushing back, citing thin clinical evidence, safety risks,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
